Does LEUPROLIDE Cause Malignant neoplasm progression? 549 Reports in FDA Database
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 549 reports of Malignant neoplasm progression have been filed in association with LEUPROLIDE (Fensolvi). This represents 0.8% of all adverse event reports for LEUPROLIDE.
549
Reports of Malignant neoplasm progression with LEUPROLIDE
0.8%
of all LEUPROLIDE reports
128
Deaths
72
Hospitalizations
How Dangerous Is Malignant neoplasm progression From LEUPROLIDE?
Of the 549 reports, 128 (23.3%) resulted in death, 72 (13.1%) required hospitalization, and 15 (2.7%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for LEUPROLIDE. However, 549 reports have been filed with the FAERS database.
What Other Side Effects Does LEUPROLIDE Cause?
Hot flush (9,146)
Death (8,772)
Intercepted product preparation error (8,621)
Syringe issue (7,847)
Device leakage (5,861)
Wrong technique in product usage process (5,062)
Fatigue (4,805)
Injection site pain (4,678)
Prostatic specific antigen increased (2,432)
Asthenia (2,176)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which LEUPROLIDE Alternatives Have Lower Malignant neoplasm progression Risk?
LEUPROLIDE vs LEVALBUTEROL
LEUPROLIDE vs LEVAMISOLE
LEUPROLIDE vs LEVAQUIN
LEUPROLIDE vs LEVEMIR
LEUPROLIDE vs LEVETIRACETAM